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Myocilin is a secreted glaucoma-associated protein, specifically induced by dexamethasone in human trabecular
meshwork cells, where it was discovered. Myocilin is expressed in several tissues of the body, but it causes
disease only in the eye. The protein contains two domains: an N-terminal region with significant homologies to
nonmuscle myosin, and a C-terminal region, which is similar to the olfactomedin proteins. Forty percent of
myocilin undergoes an intracellular endoproteolytic cleavage by calpain II, a calcium-dependent cysteine pro-
tease, which releases the 2 domains. The protein is known to interact with intracellular and extracellular matrix
proteins, and some is released into the extracellular space associated with exosomes. Myocilin mutations are
linked to glaucoma and induce elevated intraocular pressure. Most of the glaucoma-causative mutations map to
the olfactomedin domain, which appears to be a critical domain for the function of the protein. Myocilin mutants
are misfolded, aggregate in the endoplasmic reticulum, and are not secreted. Overexpression of myocilin and of its
mutants in primary human trabecular meshwork cells triggers changes in the expression of numerous genes, many
of which have been known to be involved in mechanisms important for the physiology and pathology of the tissue.
Here we review recent studies from our laboratory and those of others that deal with trabecular meshwork genes,
which are altered by the overexpression of wild-type and glaucoma-causative mutant myocilin genes.
Introduction
Ever since the discovery of the trabecular meshwork–specific induction of myocilin by dexamethasone
(DEX) (originally termed ‘‘trabecular meshwork glucocor-
ticoid-inducible protein,’’ TIGR),1,2 and of the consequent
association of the gene encoding the protein to glaucoma,3
there has been enormous interest in identifying the mecha-
nisms by which the protein causes the disease. Interestingly,
the initial discovery of an increased expression of the
wild-type form of the protein under known glaucomatous
conditions appeared contradictory to subsequent findings
involving the discovery of numerous mutations in the gene
that were linked to the disease worldwide. Mutations in the
myocilin gene amount to 3% of the global primary open-
angle glaucoma. To date, over 250 different variants have
been reported (http://www.myocilin.com/, last updated
March 17, 2013) and from those, about 40% are disease
causing. The majority of the myocilin-causing mutations
(90%) map to exon 3 of the gene, which encodes for the
olfactomedin domain of the protein (residues 244–504). Most
mutations are missense, and each of their phenotypes varies
considerably, showing glaucomas of different severities, dif-
ferent age of onset, different characteristics of the amino acid
mutated, environmental factors, etc. (review in4). Recently,
some myocilin mutations have shown association with
pigment dispersion syndrome and pigmentary glaucoma.5
Studies addressing the biology of the protein resulted in the
identification of numerous associated mechanisms such as,
among others, endoplasmic reticulum stress, cell adhesion,
intercellular communication through exosomes, involvement
of the Wnt and RhoA pathways, regulated processing of the
protein etc. It would seem quite likely that myocilin uses
more than one mechanism to induce trabecular meshwork
resistance and elevated pressure. It is well accepted that
myocilin mutations are caused by a gain of function.
An approach toward the identification of glaucoma-
causative mechanisms of myocilin has been the charac-
terization of those trabecular meshwork genes that are
modified by either overexpression of the wild-type or the
mutated forms of the protein. Although full concordance does
not occur among the different studies, there appears to be a
common trend and, importantly, all of them reveal a group
of genes with functions that could have an impact in the
regulation of aqueous humor outflow facility. In this short
review, the major alterations triggered by wild-type and
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mutated myocilin in different species and under different
conditions will be compared. A schematic summary of the
selected relevant genes and functions reviewed here is
shown in Tables 1A and 1B.
Genes Affected by Overexpression
of Wild-Type Myocilin
Microarrays
Overexpression of recombinant wild-type myocilin in
primary human trabecular meshwork (HTM) cells induces
changes in the expression of numerous genes of the cell’s
transcriptome. The latest microarray study used an adeno-
viral vector carrying the full coding myocilin gene under the
control of a ubiquitous cytomegalovirus (CMV) promoter
versus an empty vector with the same background.6 The
number of nonredundant genes altered ‡ 1.5-fold in the
myocilin-infected cells was 4337 out of 54,678 spots in the
Affymetrix Human Genome U133 Plus 2.0 chip, or ap-
proximately 8%. Of these altered genes, 2,008 were upre-
gulated and 2,329 downregulated, or approximately 50%.
These arrays were conducted with RNA from primary HTM
cells generated by the explant method from corneal rims at
passage 4, infected with a newly constructed adenoviral
vector (Adh.myocWT) and harvested at 72 h post-infection.6
An example of trabecular meshwork relevant (TMR) genes
from this wild-type myocilin list included: podoplanin
(PDPN, 4.7-fold), prostaglandin D2 synthase (PGD2, 3.4-
fold), chitinase-3-like 1 (CHI3L1, 3.0-fold) and aB-crys-
tallin (CRYAB, 1.8-fold). Some of the genes altered by the
wild-type had also been altered by some mutants.6 PDPN is
a gene that was shown to be induced by elevated pressure in
perfused human anterior segments7 and a mediator in the
activation of the RhoA pathway in lymphatic cells.8 PGD2
catalyzes the formation of prostaglandin D2, a molecule
with a long history of reducing intraocular pressure (IOP).9
CH13L1 is a trabecular meshwork marker10 and CRYAB,
expressed in the juxtacanalicular region of the trabecular
meshwork, is significantly regulated by elevated pressure.7
Earlier microarrays11 conducted with RNA from primary
HTM cells generated by the collagenase method,12 infected
with a different myocilin adenoviral vector construct,13
hybridized with the older generation Human Genome U133
A chips, and compared against vehicle-treated cells, gave a
slightly different profile. For instance, among the top TMR
changers there was an increased MMP1 (26-fold in the
array, 5.8-fold taqman PCR), thrombomodulin (THBD,
20-fold), and angiopoietin 2 (ANGPT2, 39-fold).11 These 3
genes also appeared altered in the more recent myocilin
chips, albeit some of them downregulated. MMP1 and
THBD were downregulated while ANGPT2 was increased
by the myocilin wild-type.6 The functions of these three
genes are known to influence the trabecular meshwork.
MMP1 is an interstitial collagenase known to increase out-
flow facility and lower IOP.14,15 THBD is a vascular en-
dothelial cell receptor involved in blood clotting, induced by
elevated IOP, and believed to influence the fluidity of the
aqueous humor,16,17 while ANGPT2, a pro-angiogenic
protein that acts by loosening up cell–matrix interactions,
could be a facilitator of outflow facility.
Experiments using myocilin overexpression in other
species and analyzed on their corresponding arrays yielded
additional genes. Crosses between a Drosophila melanoga-
ster transgenic line carrying the human myocilin cDNA
under the control of the UAS promoter, with the gmr-GAL4
line, carrying the transposon P(GAL4-ninaE.GMR), drove
myocilin expression to the eye of the fly. RNAs extracted
from the fly heads whose eyes overexpressed human myo-
cilin were hybridized to high-density arrays and compared
to the parental lines. Analysis of these arrays yielded 50
transcripts with very significant P-values. The highest
overexpressed gene, the swiss cheese gene, was upregulated
34-fold.18 Interestingly, the swiss cheese human ortholog,
neuropathy target esterase (NTE), was upregulated in the
trabecular meshwork of perfused human anterior segment
cultures in response to adenovirus-mediated overexpression
of wild-type myocilin.18 Among the Drosophila down-
regulated genes were a water transporter-like protein (CG4019)
and a Cytochrome P-450 isoenzyme (CYP315A1), whose
human homologs Aquaporin4 and Cytochrome P-450
(CYP315A1) have been identified as associated with aque-
ous humor dynamics and congenital glaucoma.19,20
Subjecting the mouse eye to elevated levels of myocilin
protein in the aqueous humor also caused changes in the
entire eye gene expression.21 Transgenic mice carrying
myocilin cDNA under the control of the bB1-crystallin
promoter expressed myocilin in the lens and secreted the
protein into the aqueous humor. Transcriptome of the whole
mouse eye (minus the lens) was compared to that of the
wild-type littermate. Hybridization to Affymetrix mouse
430 2.0 arrays yielded 7 differentially expressed genes with
fold change values ‡ 1.5 and significant P-values lower than
0.05. Of the top changers, connexin 46 (Gja3), aB-crystallin
(Cryab), and spondin 2 (Spon2) were increased 5.0-, 1.9-
and 1.6-fold, respectively. The other 4 genes, homeobox
protein SIX1 (Six1), cyclin-dependent kinase 14 (Pftk1),
neural Wiskott-Aldrich syndrome protein (Wasl) and carci-
noembryonic antigen1 (Ceacam1) were down-regulated
between 1.8- and 1.7-fold. In a similar manner to what it
occurred in the fruit fly, the expression change of the cor-
respondent human genes was reproduced in primary HTM
cells. For that, RNA extracted from HTM cells exposed to
different concentrations of recombinant myocilin (isolated
from supernatants of HEK293 cells transfected with a
recombinant myocilin plasmid) showed concordant down-
regulation of SIX1, PFTK1, WASL, and CEACAM1 and re-
versed (down- rather than up) regulation of SPON2.21 SIX1 is a
transcription factor, PFTK1 is a cycle-dependent kinase, WASL
is a cytoskeletal signaling protein, and CEACAM1 and SPON2
are involved in cell adhesion. The functions of the proteins
encoded by these genes would be relevant to regulation of
outflow facility by the trabecular meshwork. The overlapping
up-regulation of CRYAB in human cells and transgenic mice
gives this gene a stronger myocilin mediator role. A list of
selected relevant genes from this section is shown in Table 1A.
Single-function studies: stress fibers, RhoA, Wnt
pathway, and osteogenesis
Several studies on the overexpression of myocilin in the
trabecular meshwork have focused on the effect of high
levels of the protein on a given cell function. Yue’s team
constructed a pcDNA3.1 plasmid containing the coding
myocilin cDNA, the CMV promoter, and the V5 and 6XHis
tags at its 3’-end. The authors overexpressed the gene
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by transfecting primary HTM cells, either by the use of
hemagglutinating virus of Japan (HVJ)-liposome system22
with harvesting at 48 h, or by generating stably transfected
cells using the FuGene kit (La Roche) and G418 selection.
In both transfection methods, an increase in myocilin levels
by 3- to 4- fold caused a significant loss of actin fibers and
focal adhesions.23 In contrast, studies from a different
group24 reported that treatment of primary HTM cells with
exogenous purified myocilin induced the formation, not the
loss of stress fibers. Interestingly, both groups showed that
Table 1A. Selected Trabecular Meshwork Relevant Genes Altered by Wild-Type and Mutant Myocilin




model Species Analysis Function Citation
Wild-type Myocilin
Podoplanin PDPN 4.7 HTM cells* Adh.myocWT Human AffyU133P2.0 Lymph.marker/ Rho activ. Kennedy 2012
Prostaglandin D2 synthase PTGDS 3.4 HTM cells* Adh.myocWT Human AffyU133P2.0 Neuromodulator Kennedy 2012
Chitinase 3-like 1 CHI3L1 3.0 HTM cells* Adh.myocWT Human AffyU133P2.0 Cartilage ECM Kennedy 2012
aB-Crystallin CRYAB 1.8 HTM cells* Adh.myocWT Human AffyU133P2.0 Chaperone Kennedy 2012
Matrix metallopeptidase 1 MMP1 26.0 HTM cells** AdhTIG3.WT Human AffyU133 A ECM remodeling Borrás 2006
Thrombomodulin THBD 20.0 HTM cells** AdhTIG3.WT Human AffyU133 A Binds thrombin/clotting Borrás 2006
Angiopoietin 2 ANGPT2 39.0 HTM cells** AdhTIG3.WT Human AffyU133 A Pro-angiogenic Borrás 2006
Swiss cheese sws 34.0 Transgenic* UAS-WT Drosophila AffyDros 2.0 Neurodegenerative prt. Borrás 2003
Aqp1049 CG4019 - 1.8 Transgenic* UAS-WT Drosophila AffyDros 2.0 Water chanel activity Borrás 2003
Cytochrome P450 CYP315A1 - 2.6 Transgenic* UAS-WT Drosophila AffyDros 2.0 Detoxification Borrás 2003
Conexin46 Gja3 5.0 Transgenic** bB1-Cry-Myoc Mouse Affy 430.2.0A Gap junct/cell-cell sign. Paper 2008
aB-Crystallin Cryab 1.9 Transgenic** bB1-Cry-Myoc Mouse Affy 430.2.0A Response to heat Paper 2008
Spondin Spon2 1.6 Transgenic** bB1-Cry-Myoc Mouse Affy 430.2.0A Cell adhesion Paper 2008
Homeobox protein Six1 Six1 - 1.8 Transgenic** bB1-Cry-Myoc Mouse Affy 430.2.0A Transcription factor Paper 2008
Neural Wiskott-Aldrich prt. Wasl - 1.8 Transgenic** bB1-Cry-Myoc Mouse Affy 430.2.0A Cytoskeleton signaling Paper 2008
Carcinoembryonic antigen1 Ceacam1 - 1.7 Transgenic** bB1-Cry-Myoc Mouse Affy 430.2.0A Cell adhesion Paper 2008
Myocilin mutants
Q368X
Prot disulfide isomerase A4 PDIA4 2.1 HTM cells* Adh.Q368X Human AffyU133P2.0 Chaperone Kennedy 2012
Secret frizz-related prot 1 SFRP1 - 2.5 HTM cells* Adh.Q368X Human AffyU133P2.0 Wnt signaling Kennedy 2012
Matrix Gla protein MGP - 2.0 HTM cells* Adh.Q368X Human AffyU133P2.0 Inhibitor of calcification Kennedy 2012
Lysyl oxidase-like 1 LOXL1 - 2.0 HTM cells* Adh.Q368X Human AffyU133P2.0 Elastin network Kennedy 2012
Heat shock prot 90B1 (GRP94) HSP90B1 3.3 HTM cells* Adh.Q368X Human AffyU133P2.0 Unfo Prot Respon (UPR) Kennedy 2012
Calreticulin CALR 2.3 HTM cells* Adh.Q368X Human AffyU133P2.0 Unfo Prot Respon (UPR) Kennedy 2012
Glycoprotein 93 Gp93 up Transgenic* UAS-Q368X Drosophila AffyDros 2.0 Unfo Prot Respon (UPR) Carbone 2009
Calreticulin Crc up Transgenic* UAS-Q368X Drosophila AffyDros 2.0 Unfo Prot Respon (UPR) Carbone 2009
R342K
Ras-related protein 39B RAB39B 3.2 HTM cells* Adh.R342K Human AffyU133P2.0 Vesicular trafficking Kennedy 2012
D380N
Matrix metallopeptidase 1 MMP1 - 5.5 HTM cells* Adh.D380N Human AffyU133P2.0 ECM remodeling Kennedy 2012
Fibronectin 1 FN1 1.8 HTM cells* Adh.D380N Human AffyU133P2.0 Cell adhesion Kennedy 2012
Synuclein alpha SNCA 2.5 HTM cells* Adh.D380N Human AffyU133P2.0 Presynaptic signal Kennedy 2012
K423E
Insulin-like growth factor 1 IGF1 3.9 HTM cells* Adh.K423E Human AffyU133P2.0 Signaling hormone Kennedy 2012
Cytochrome P450, 1B1 CYP1B1 - 2.7 HTM cells* Adh.K423E Human AffyU133P2.0 Detoxification Kennedy 2012
Q368X, R342K,D380N,K423E (of 73 shared)
Chemokine (C-X-C motif)12 CXCL12 - 3.0 HTM cells* Adh.Q368X Human AffyU133P2.0 Signaling cytokine Kennedy 2012
Cystatin A (Stefin A) CSTA 3.4 HTM cells* Adh.R342K Human AffyU133P2.0 Protein processing Kennedy 2012
Endothelin 1 EDN1 - 1.6 HTM cells* Adh.D380N Human AffyU133P2.0 Vasoactive peptides Kennedy 2012
Stanniocalcin 1 STC1 - 1.8 HTM cells* Adh.K423E Human AffyU133P2.0 Calcium homeostasis Kennedy 2012
P370L
Glucose-reg Prot78 (BIP) GRP78 - 1.5 HTM cells* pcDNA3.P370L Human WB Unfo Prot Respon (UPR) Wang 2007
Y437H
Glucose-reg Prot78 (BIP) GRP78 up HEK 293*. Y437H Human WB Unfo Prot Respon (UPR) Joe 2010
Protein disulfide isomerase PDI up HEK 293* Y437H Human WB Chaperone Joe 2010
I477N
Glucose-reg Prot94 (HSP90B1) GRP94 up HEK 293**. I477N Human co-IP Unfo Prot Respon (UPR) Suntharalingam
2012
Protein disulfide isomerase PDI up HEK 293** I477N Human WB Chaperone Joe 2010
Glucose-reg Prot78 (BIP) GRP78 up HEK 293** I477N Human WB Unfo Prot Respon (UPR) Joe 2010
ECM Protein synthesis/modification Stress / defense Cytoskeleton/structural Signaling/cytokines Calcification
HTM cells*, primary human trabecular meshwork cells derived directly from TM explants; HTM cells**, primary human trabecular
meshwork cells derived from collagenase treatment of TMs.
Transgenic*, Heads from transgenic flies.
Transgenic**, Mouse eyes (minus lens) from transgenic mice.
HEK 293*, HEK 293 Tet-On stably transfected with pTRE-Y437H MYOC.
HEK 293**, HEK 293 Tet-On stably transformed with pTRE-I477N MYOC.
HTMs, human trabecular meshworks; WB, Western blot; ECM, extracellular matrix.
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either the loss, or the induction of stress fibers induced by
myocilin was reverted by treatment of the cultures with
secreted frizzled-related protein 1 (SFRP1), an inhibitor of
the Wnt pathway.24,25 This would indicate that the actions of
wild-type myocilin in the cells were mediated by the Wnt
pathway. In addition to the Wnt pathway interfering with
cell characteristics induced by myocilin, it was also pro-
posed that, reversely, myocilin could itself be a modulator of
the Wnt pathway.24 Immunoprecipitation experiments have
demonstrated the interaction of myocilin with SFRP1,
SFRP3, and several frizzled receptors, and treatment of
murine NIH3T3 cells with recombinant purified human
myocilin protein induced cellular translocation of b-catenin,
albeit not to the nucleus as occurs in the canonical Wnt
pathway.24 The activation of the Wnt pathway by (in-
creased?) myocilin was also shown by a direct assay using
TOP-Flash/FOP-Flash luciferase reporter plasmid.25 This re-
porter plasmid contains 2 repeats of three copies of the Tcf/
Lef binding site in front of a basic promoter driving the lu-
ciferase gene, and it is activated by b-catenin. Co-transfection
of the myocilin and pTOP-Flash plasmids into human colo-
rectal carcinoma cells induced a 2.7-fold activation of lucif-
erase (Wnt pathway) over controls. However, when the
co-transfection was performed into primary HTM cells, the
increase of luciferase and thus of the Wnt pathway was
marginal.25 It is likely that in this experiment, as the authors
interpret, the very low Wnt induction in cells of the outflow
facility was due to low transfection efficiencies. Although the
presence of the Wnt pathway in the trabecular meshwork has
been demonstrated,26,27 newer designs overcoming transfec-
tion barriers are needed to ascertain the correlation of myo-
cilin with this pathway in the trabecular meshwork.
In addition to the loss of stress fibers, adhesion assays
have shown that increased myocilin tends to diminish ad-
hesion of the cells to the extracellular matrix (ECM),
making it logical to speculate the existence of a correlation
of these events with a beneficial outcome for regulation of
outflow facility.28 Supporting these effects are experiments
where coating cell culture dishes with myocilin isolated
from transfected Sf9 insect cells inhibited cell spreading of
human neonatal skin fibroblasts, and treating these same
cells with the soluble protein inhibited incorporation of
paxillin into focal adhesions.29 At the same time, though, it
was observed that cells containing high levels of myocilin
exhibited an increased sensitivity to apoptosis, which would
indicate that cells overexpressing the wild-type are sicker
and more subjective to pathological events.23 Based on such
overexpression experiments, it would seem that myocilin
might be involved in a balancing act between an association
of the disruption of cytoskeleton/adhesion with increased
outflow facility and a weaker cell, which would compromise
coping with oxidative stress and/or other insults.
Myocilin also reduced the deposition of fibronectin and
the activity of RhoA as measured by the pull-down assay.30
Furthermore, the loss of actin stress fibers in cells over-
expressing myocilin was prevented by co-transfection with a
constitutive active RhoA plasmid.30 Altogether, those find-
ings suggested that at least some overexpressed myocilin
effects might be mediated through the regulation of the
RhoA pathway.
An intriguing recent finding on myocilin effects is that of
its role in the differentiation of mesenchymal stem cells
(MSC) into osteoblasts, and in osteogenesis in vivo. Myo-
cilin was detected in human bone-marrow-derived MSC,
Table 1B. Selected Trabecular Meshwork Functions Altered by Wild-Type and Mutant Myocilin
Function Model Method Vector Species Citation
Wild-type myocilin
Loss of stress fibers Transi.transf.HTM/ HVJ liposome/ 48h Immunofluoresc.Phalloidin pcDNA3.1.myoc Human Wentz-Hunter
2004
Stably transf.HTM cells/ FuGene Immunofluoresc.Phalloidin Human
Induction stress fibers Exogen myoc on HTM / 3h Immunofluoresc.Phalloidin purified myocilin Human Kwon 2009
from transfec 293 media
b-Catenin translocation Exogenous myoc on NIH3T3 cells Immunofluoresc.bcatenin from transfec 293 media Mouse Kwon 2009
Wnt pathway activation Tcf/Lef binding site/ luciferase reporter Chemiluminescence Myoc + pTOP-Flash Human Shen 2012
Transf.Colorectal adenocarcinoma cell
Reduce RhoA activation Transi.transf.HTM/ FuGene&Lipof.LTX Pull-down assay pTarget.myocilin Human Shen 2008
Reduce fibronectin deposition Transi.transf.HTM Fluores. Histocytochem. pTarget.myocilin Human Shen 2008
Higher sensitivity to apoptosis Transi.transf.HTM/ HVJ liposome/ 48h Anti-Fas apoptosis inducti pcDNA3.1.myoc Human Wentz-Hunter
2004
Conversion to osteoblasts Mesenchimal stem.cells (MSC) AlizaRed stain./Alkal.Phos. purified myocilin Human Kwon 2013
3mg myoc for 6d from transfec 293 media
Inhibits cell spreading Hskin fibroblast on coated myoc well Count spread/round cells Hmyoc fr transf insectcells Human Peters 2005
Inhibits incorp Paxillin in FA Hskin fibrobroblast + soluble myocilin Immunofluoresc. Vin&paxil Hmyoc fr transf insectcells Human Peters 2005
Mutant myocilin
Disturbs ER stress response Transi.transf.HTM/ Lipofectmine pcr.GRP78 & P.eIF2a pCDNA3.P370L Human Wang 2007
Disturbs Mitchon membr potential Transi.transf.HTM/ Lipofectmine Flow cytometry. JC1probe pCDNA3.P370L Human Wang 2007
Loss of stress fibers Transi.transf.HTM/ FuGene&Lipof.LTX FuGene & Lipofecta.LTX pMyoc.P370L-EGFP Human Shen 2012
Increase prot kinA (PKA) activitity Transi.transf.HTM/ FuGene&Lipof.LTX Peptag L-R-R-S-L-G pMyoc.P370L-EGFP Human Shen 2012
Reduce RhoA activation Transi.transf.HTM/ FuGene&Lipof.LTX Pull-down assay pMyoc.P370L-EGFP Human Shen 2012
Incre sensitivity to oxidative stress HEK 293*/ 100mM H2O2 Apoptosis/ TUNEL pTRE-Y437H MYOC Human Joe 2010
Mild glaucoma Transg.mice/ hmyoc IOP/ RGC&Axon count BAC RP11-23L17.Y437H Mouse Zhou 2008
Glaucoma Transg.mice/ CMV.cDNAhmyoc IOP/ RGC&Axon count pCS2.Y437H Mouse Zode 2011
Inhibition of myoc processing Transi.transf. HEK293, COS, hCMsv WB pCDNA3.D380A H &Monk Aroca-Aguilar 2005
HEK 293*, HEK 293 Tet-On stably transfected.
HTM, primary human trabecular meshwork cells; ICC, immunocytochemistry; FA, focal adhesion; ER, endoplasmic reticulum; IOP,
intraocular pressure.
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and treatment of the cultures with purified myocilin en-
hanced osteogenesis as measured by alizarin red staining.31
Evidence of the existence of a calcification process in the
trabecular meshwork was first introduced in 2006 by Xue
et al.,32 followed by a second report on the increased con-
centration of the calcification marker alkaline phosphatase
in the trabecular meshwork of postmortem glaucomatous
specimens.33 It was hypothesized then that this process
could involve the conversion of HTM cells into osteo-
blasts.33 Whether myocilin is mediating this process is not
yet known. It is well established that induction of the Wnt
pathway promotes calcification and osteogenic differentia-
tion.34,35 Perhaps then, the induction of osteogenesis by
myocilin is mediated by its activation of the Wnt pathway.
This newly described property of myocilin could implicate
overexpressed myocilin as having a detrimental role in
outflow facility and inducing elevated IOP. A list of selected
relevant functions from this section is shown in Table 1B.
Genes Affected by Overexpression
of Glaucoma-Causative Myocilin Mutants
Mutants in myocilin have been undoubtedly linked to
glaucoma. Moreover, there is no direct evidence in the
global population that overexpression of wild-type myocilin
is linked to the disease or to glaucomatous conditions in
humans. The paradox exists though, in the cases of medical
treatment with corticosteroids. Topical ocular treatment
with corticosteroids induces elevated IOP in 30%–40% of
the population, and these responders are more likely to de-
velop primary open-angle glaucoma than the nonresponders.
It is quite intriguing, then, that treatment of trabecular
meshwork tissue and cells with DEX specifically induces
myocilin.2,36 Morphological characteristics observed on the
outflow pathway of human specimens with steroid-induced
glaucoma indicate that the cause of elevated pressure is an
increased ECM deposition. It is well known that cortico-
steroids elicit alteration of expression in a multitude of
genes, many of them associated with remodeling of the
ECM.37 Thus, whether other DEX-induced genes are in-
volved, or whether myocilin overexpression is the central
mediator of glucocorticoid-associated glaucoma is not
known, but it would seem less likely. On the contrary, nu-
merous myocilin mutations have been strongly linked to
families and individuals with glaucoma (http://www.myocilin
.com/). A number of studies have searched for the genes
affected by overexpression of different myocilin mutation
mutants.
Microarrays
Our laboratory conducted a thorough comparative study
using 4 selected glaucoma-causative myocilin mutations
(Q368X, R342K, D380N, and K423E), primary HTM cells
from the same individual and passage number, and Affy-
metrix U133 Plus 2.0 GeneChips.6 Each mutant cDNA was
carried on an adenoviral vector and compared to an adeno-
null control; the cutoff for differential expression was 1.5-
fold. The 4 representative mutants were selected based on
different clinical outcomes, population, or relevance of the
mutated codon. The Q368X variant is the most common
(31.3% of the disease-causing variants, http://www.myocilin
.com/), and results in a mild phenotype (mean IOP
21 mmHg); mutations R342K and D380N comprise 0.7% of
the causing variants each, and are very severe, with a mean
maximum IOP of 54 and 39 mmHg, respectively.38 The
amino acid #380, aspartic acid, highly conserved in all
vertebrates, has produced 4 disease-causing variants,4 an
extremely rare occurrence in genetics. The fourth selected
mutant, K423E (mean IOP 31 mmHg), was selected because
it occurred in two unrelated Caucasian populations, has a
severe clinical outcome and presents the interesting feature
that homozygous patients do not develop the disease.39
Gene lists generated from each of the human myocilin
mutants shared different percentages of altered genes with
the myocilin wild-type (Fig. 1). Thus, 64% of genes altered
by the stop mutation Q368X did not overlap with genes
altered by the wild-type, the highest nonoverlapping pro-
portion of the 4 mutants. Mutant R342K, which had the
lowest absolute number of altered genes, still contained a
high 56% nonoverlap. The other 2 mutants, D380N and
K423E, had a lower number of nonoverlapping genes (24%
and 22%, respectively), sharing more of the changes with
the wild-type (Fig. 1A). Regarding affecting the trabecular
meshwork transcriptome, these 4 mutations appear to fall
into 2 sets: Q368X/R342K (set 1) and D380N/K423E (set
2), at both the overall and individual affected gene level.
This categorization does not correlate with their IOP out-
come. All 4 mutants shared just 73 altered genes among
themselves. Among these 73 genes were the signaling cy-
tokine CXCL12, the vasoconstrictor endothelin 1 (EDN1),
the ECM protein ECM2, the cysteine protease Cystatin A
(CSTA), the calcium homeostasis proteins stanniocalcin 1
and 2 (STC1, STC2), and the growth factors insulin-like
growth factor 1 (IGF1) and fibroblast growth factor 1
(FGF1).6 Together these genes encode proteins with nu-
merous diverse functions, from signaling, to matrix com-
ponents, to calcium regulation. It is likely that a
combination of their encoded functions would be responsi-
ble for the glaucoma caused by myocilin. Furthermore, of
the 73 shared altered genes, 10 were not altered in the wild-
type. One of them (CSTA, a cysteine protease inhibitor) is
described below.
Among the individually affected candidate genes (i.e.,
genes that were top-changers in just 1 of the 4 mutants),
there were many that had been historically connected to
trabecular meshwork physiology and pathology. Some of
them had known myocilin associations such as MMP1,
calreticulin (CALR), protein disulfide isomerase 4 (PDIA4),
secreted frizzled-related protein 1 (SFRP1), and fibronectin
1 (FN1) while others did not, such as EDN1, Matrix Gla
(MGP), and IGF1. Some of the genes were top-changers
only in 1 of the mutants such as lysyl oxidase-like 1
(LOXL1) or Cytochrome P450 family 1B1 (CYP1B1) (in
mutations Q368X and K423E, respectively), pointing to an
individual response to a particular mutant. Some of the
found genes were also new to the field, such as synuclein
alpha (SNCA), STC1, CXCL12, and CSTA.6 In each case,
however, it is not difficult to speculate that their specific
encoded functions could be potential modulators of outflow
facility, giving myocilin a wide range of possibilities by
which it could cause glaucoma.
In this human study,6 lists of genes representing 4 rele-
vant trabecular meshwork functions [those of stress and
unfolded protein response (UPR), Wnt pathway, collagen-
elastin crosslinking and calcification genes] were custom
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generated by literature review and analyzed in the 4 mu-
tants.6 Two of the 4, the WNT pathway and the UPR, are
shown in Fig. 2. These expression heat maps have revealed
that the gene list comprising the endoplasmic reticulum
(ER) stress/UPR were the most affected and up-regulated, in
particular by Q368X and R342K mutants. Curiously, the
same mutants caused the most down-regulation for the set
of genes of the Wnt pathway (Fig. 2). A Drosophila
study using the gmr-Gal4/UAS system described above used
the same set of myocilin mutants and analyzed the RNA of
FIG. 1. Venn maps of genes of the
trabecular meshwork altered by over-
expression of wild-type and 4 glaucoma-
causative myocilin mutants. Hybridization
was conducted on Affymetrix GeneChips
(n = 17) and analyzed with GeneSpring 10
software. Nonredundant gene lists had
cutoff fold-change values of ‡ and £ 1.5.
(A) Number of genes altered in each of
the mutants that overlap with genes al-
tered by the wild-type. (B) Number of
genes altered in all mutants.6
FIG. 2. Heat maps depicting
changes induced by myocilin mu-
tants on the WNT pathway and
Unfolded Protein Response trabec-
ular meshwork genes. Gene lists for
each pathway were custom-gener-
ated by literature review. Each row
represents the fold change (Adeno
.myocilin.mutant over Adeno.Null)
for a single gene in each of the 4
mutants. Each column represents
the fold changes for all genes of the
category in one myocilin mutant.
The fold change for each gene is
visually represented by a color,
which is given by the scale bar on
the right. Gray cells indicate that the
expression of the given gene was
below the signal intensity cutoff
value and was considered absent.
Modified from reference 6 with
permission.
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2–3-day-old whole fly heads in their corresponding arrays.40
Interestingly, the UPR response genes were also altered in
the myocilin mutant flies and as in the human, the Q368X
mutant was the one having a major effect. Moreover, to
confirm the UPR response elicited by the myocilin mutants,
these authors generated myocilin mutant flies carrying an
additional green fluorescent protein (GFP) reporter gene
under the control of an ER response element.41 Although a
considerable amount of autofluorescence was present, a
punctate GFP expression was clearly observed in the mutant
flies, especially in the Q368X mutant.40 This correlation of
elicited functions known to be induced by ER stress between
such diverse species as human and insects gives a greater
strength to validity of the UPR response, and at the same
time validates the fly system as a good genetic model of
glaucoma. A list of selected relevant genes from this section
is shown in Table 1A.
Focused myocilin mutant studies
Two other myocilin mutations associated with early-
onset, or juvenile open-angle glaucoma, Y437H and P370L,
have been the subject of several studies. The Y437H mu-
tation was first described in 1998,42 amounts to 7.3% of the
myocilin disease-causing variants, and has a mean IOP of
43.7 mmHg (mean age of diagnosis, 19.1 years). The P370L
is 3.9% of the variants, has a mean IOP of 29.8 mmHg, and a
mean age of diagnosis of 13 years.
Overexpression of the P370L in primary HTM cells for
40 h was found to down-regulate the ER stress response and
to damage the mitochondrial membrane potential.43 In that
study, ER stress was induced with 2.5 mg/mL of tucana-
mycin for 6 h and evaluated by the expression levels of
glucose-regulated protein GRP78 (also known as BIP).
Mitochondrial membrane potential was measured by ex-
posing the cells to the JC-1 fluorescence probe for 15 min,
harvesting the cells, and analyzing them immediately by
flow cytometry. In a different laboratory, and also using
HTM cells, the same P370L mutation caused loss of actin
stress fibers, an increase in protein kinase A (PKA) activity,
and Rho inactivation.25 The PKA increase was reverted by
treatment with SFRP1, an inhibitor of the Wnt pathway.
The human myocilin gene, containing the Y437H muta-
tion with its own promoter and regulatory regions, was used
to generate transgenic mice. The human gene was expressed
in the mouse eye and produced changes that, although
moderate, were characteristic of glaucoma.44 HEK293 cells
stably transformed with the same myocilin mutant were more
sensitive to oxidative stress and up-regulated the chaperone
ER stress marker GRP78.45 Importantly, a second trans-
genic mouse generated in a different laboratory and carry-
ing the human myocilin Y437H cDNA driven by a CMV
promoter developed a more robust glaucomatous phenotype
and induced ER stress.46 This transgenic mouse showed
elevated IOP plus retinal ganglion cells and axon degen-
eration at 3–4 months of age.46 Moreover, topical admin-
istration 2 · daily with a 0.2% solution of sodium
4-phenylbutyrate (PBA) significantly reduced the elevated
IOP in these mice.47 PBA is a clinically approved chemical
chaperone, which has been shown to reduce ER stress in
several diseases.47 Together, all these findings corroborate
the relevance of the ER response in the myocilin mutant
trigger of glaucoma.
One of the hallmarks of myocilin mutant effects is that of
being sequestered inside the cell. A study comprising 26
glaucoma-linked variants showed that 20 of them were re-
tained intracellularly and 6 were secreted (80% secreted).48
When the temperature of the incubator was lowered from
37C to 30C, a process known to facilitate protein folding,
11 of the 20 mutants originally retained were now secreted.
Lowering the temperature also increased the originally
lower secretion level of variant T377M to that of the other
secreted variants.48 The variant T377M comprising 14.8%
of the glaucoma-linked mutations exhibits a moderate
IOP (16.7 mmHg) with an age of onset of 21.4 years of age.
The sequestration of the myocilin mutants is not specific
to glaucoma-causative mutations but is most likely due to
localization of the mutation to the olfactomedin domain of
the protein. This sequestration was first reported in a labo-
ratory-created arbitrary mutant in the olfactomedin do-
main.49 All data together strongly indicates that myocilin
mutants are misfolded. Proteins that fail to fold correctly
are sequestered at the ER and induce ER stress.50 Hetero-
oligomers of myocilin wild-type/mutants have also been
shown to be sequestered in the ER51 and to activate the same
UPR response genes that are seen after overexpression of
myocilin variants.6,40 The overwhelming majority of
myocilin-causative glaucoma occurs in heterozygous indi-
viduals, where the formation of wild-type/mutant hetero-
oligomers leads to the formation of insoluble aggregates.49,51
Four cases of myocilin mutation homozygosity have been
reported.39,52–54 The T377M homozygous (2 subjects)
presents a glaucoma that is more severe than its more fre-
quent heterozygous state,50 the variants K423G (4 sib-
lings)39 and G368X (1 subject)53 present normal ocular
exams, and the fourth variant reported, R46X, appears to be
a neutral mutation.52
Recently, it has been discovered that the aspartic acid
amino acid 380, which as described above, leads to the
unusual event of 4 different glaucoma-causative mutants
(D380N, D380A, D380G, and D380H),55 is an integral part
of a calcium-binding site buried in the olfactomedin do-
main.56 The glaucoma phenotypes corresponding to the 4
residue substitutions of aspartic acid 380 present a clinical
onset that is intermediate between juvenile and adult-onset
glaucoma. Their IOPs are also intermediate between the
severe ones of P370L and the milder one of the most
common Q368X. The aspartic acid 380 residue appears to
be important for myocilin function.55 The variant D380A
significantly inhibits the endoproteolytic processing of
myocilin and its triton solubility,57 and the variant D380N
specifically elevates Cystatin A, which also inhibits the
myocilin processing.6 The newly found role of D380 in the
calcium-binding domain of the myocilin protein adds to its
importance and brings up the relevance of calcium on the
olfactomedin domain stability.56 It also points to an in-
volvement of myocilin in the trabecular meshwork tissue
calcification, which has been documented to be associated
with glaucoma postmortem specimens.4 These data would
be in good agreement with 1 of the functions of the calcium
binding sites, which is conferring thermal stability and
proteolytic protection to extracellular proteins.58
Another gene, HSP90B1, is upregulated by myocilin
mutants,6 especially by the Q368X mutation, which triggers
the highest UPR response.6 This gene is most recently
known as GRP94 and encodes a chaperone, ER resident
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protein, which has been shown to have unique characteris-
tics and be of special importance in the ER. GRP94 is in-
duced upon glucose deprivation, and its up-regulation is
used as a hallmark of responses of the ER to stress.59 Recent
studies have shown that myocilin is a client of GRP94 and
that this chaperone specifically recognizes the mutant
myocilin and targets it for degradation via the ubiquitin-
dependent/proteasome ER degradation (ERAD).60 Using
HEK293 cells, the authors demonstrated that silencing
GRP94 with siRNA diverts the mutated protein for degra-
dation via the more robust autophagy pathway. Although the
results need to be validated in HTM cells, where mutant
myocilin directly affects the outcome of IOP function, they
nevertheless bring an interesting rational mechanism that
could explain why myocilin mutants cause glaucoma. Still,
there is a lack of correlation between up-regulation of
HSP90B1, encoding GRP94, and the severity of the IOP
associated with the mutants. The stop mutation Q368X as-
sociated with moderate IOP (mean IOP 21 mmHg) induces
high up-regulation of the HSP90B1 gene, while mutations
D380N and K423E with means IOP of 39 mmHg and
28 mmHg barely show up-regulation of the same chaperone
(Fig. 2).6 A list of selected relevant functions from this
section is shown in Table 1B.
One Potential Common Gene Link
for Myocilin Disease-Causing Mutants:
Cystatin A
It is unlikely that one single mechanism would govern the
glaucoma-causative effect of all myocilin mutants. Myocilin
wild-type per se exerts and affects numerous cell process-
es.22–24,30,31 However, because most myocilin disease vari-
ants fall in the olfactomedin domain, it would make sense to
assume that a potential common mechanism would be one
that implicates this region of the protein. In normal condi-
tions, 40% of wild-type myocilin gets cleaved in the ER by
the cysteine protease calpain II between amino acids argi-
nine 226 and Ieucine 227, which are located in the central
linker between the 2 protein domains. This processing re-
leases a 35-kDa fragment containing the olfactomedin do-
main, which is co-secreted with the wild-type.57 Although
an olfactomedin domain fraction purified from the medium
of 293 EBNA cells transfected with a human myocilin
cDNA plasmid did not affect outflow facility in perfused
human and porcine eyes,61 the full consequences of this
domain and of this processing are not yet known. It has been
shown that myocilin mutants inhibit the proteolytic process,
and that the extent of the inhibition correlates with the se-
verity of the glaucoma phenotypes. It is also known that this
proteolytic process modulates the molecular interactions
of myocilin and reduces the formation of myocilin homo-
aggregates.62
As mentioned above, the search for specific genes that
would be involved in a common myocilin mutant mecha-
nism led to the finding that 73 genes had been altered after
overexpression of all 4 mutants of the study (Q368X,
R342K, D380N, and K423E). From those 73 genes, only 10
were altered specifically in the mutants but were not shared
with the altered genes in the wild-type.6 Analysis of the
functions of the 10 genes revealed the presence of a cysteine
protease inhibitor, Cystatin A (CSTA), which showed a no-
change 1.0-fold in the myocilin wild-type and an increase of
3.4, 3.2, 1.5, and 1.9-fold in Q368X, R342K, D380N, and
K423E, respectively.6 Functional assay of CSTA in primary
HTM cells and transformed H293K cells showed that indeed
this protein inhibited the proteolytic cleavage of wild-type
myocilin. Because the protein involved in the processing of
myocilin is a cysteine protease and because myocilin
cleavage is inhibited by myocilin mutants, it is logical to
assume that CSTA plays a role in the inhibition process.6,57
It is not yet known whether the elevation of expression of
CSTA in the myocilin mutants is directly inhibiting calpain
II. The cysteine protease CSTA inhibits the activity of the
papain-type proteases cathepsin B, L, and H. However,
CSTA was not known to inhibit calpains. However, a recent
study investigating cell death in macrophages has shown
that calpain activation occurs downstream of cathepsin B,
therefore concluding that cathepsin B activates calpain.63
Since CSTA inhibits cathepsin B, CSTA will in turn prevent
the activation of calpain. It is possible then, that increased
levels of CSTA seen in myocilin mutant cells would result
in the inactivation of calpain by inhibiting cathepsin B. All
together these gene and protein findings from 2 unrelated
laboratories do reinforce the mechanism of myocilin pro-
cessing as a potential common link of myocilin mutants.
Conclusions
Because of the continuous global finding of genetic
linkages of myocilin mutants with glaucoma (http://
www.myocilin.com/), the search for the function(s) of this
protein is of great relevance. Understanding its biology and
mechanisms leading to the disease could lead to the design
of new rational drugs. The approach of elucidating myocilin
function through the identification of genes altered by
overexpression and underexpression of wild-type and mu-
tants in the relevant cell type provides the first insight
into those mechanisms. Studies of the last decade have
demonstrated that most likely there is not a single central
mechanism associated with myocilin-causative glaucoma.
Analyses of gene profiles, as well as of individual functions
associated with them, have revealed the involvement of
numerous distinct mechanisms. Most of these, when ana-
lyzed individually, do make good physiological sense as
would-be contributors to the maintenance of aqueous humor
resistance. This is in part due to the universal role of tra-
becular meshwork tissue of maintaining a physiological
IOP. Given the nature of the tissue, it is not difficult to
visualize that such function could be achieved through many
different pathways, from the reorganization of the ECM and
contractility status of its cells, to the inhibition of calcifi-
cation and stiffness, to its processing and/or intercellular
signaling. The trabecular meshwork may use them sepa-
rately or together to exert its function. Many myocilin-
causative mechanisms remain to be learned, but many have
been found. The relatively minor discrepancies seen among
different laboratories will need to be resolved, but they may
also be an indication that the properties of this gene/protein
are very much in tune with different experimental condi-
tions. Thus, different individual cell lines, passages, and cell
culture conditions could cause an apparently different result.
Overall, identification of consequent altered gene expression
remains one of the best tools to further explore the myocilin
contribution to glaucoma. Nature usually does not waste
resources, and cells would not be using them unless the
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genes expressed would be needed for something. Keeping
an open mind and observing these genes’ changes can take
us to the design of numerous targeted drugs for controlling
elevated IOP and as a consequence to ameliorate glaucoma.
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